For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ZEUS

Trial Overview

Official Title

Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation.

Study Purpose

An interventional, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, multi-national CVOT designed to evaluate the effects of 15 mg ziltivekimab versus placebo (randomised 1:1), both administered s.c. once-monthly and added to standard of care, on CV outcomes in participants with established ASCVD, CKD and systemic inflammation.

Diagnosis

ASCVD, CKD and systemic inflammation.

Eligibility

ASCVD, CKD and systemic inflammation.

Intervention

  • ziltivekimab 15 mg/mL single-use pre-filled syringe (1 mL)
  • placebo single-use pre-filled syringe (1 mL) 

For more information, visit clinicaltrials.gov.

Key Participation Requirements
Trial Location(s)
Gender
All genders
Age
19 years or older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
NCT05021835